Table 2.
Response outcomes of patients with NPM1-mutated MDS based on type of therapy
| Response | Total (N = 28)* | Chemotherapy (n = 10)* | HMAs (n = 18)* | OR (95% CI) | P |
|---|---|---|---|---|---|
| ORR | 25 (89) | 10 (100) | 15 (83) | 0.83 (0.68-1.0) | .533 |
| PD | 3 (11) | 0 (0) | 3 (17) | 0.83 (0.68-1.0) | .533 |
| HI | 3 (11) | 0 (0) | 3 (17) | 0.78 (0.61-0.99) | .265 |
| mCR† | 7 (25) | 1 (10) | 6 (33) | 0.22 (0.2-2.2) | .364 |
| PR | 2 (7) | 0 (0) | 2 (11) | 0.89 (0.75-1.0) | .524 |
| CR | 14 (50) | 9 (90) | 5 (28) | 23.4 (2.3-235.5) | .004 |
HI, hematological improvement; mCR, marrow CR; OR, odds ratio; PD, progressive disease; PR, partial response.
*
Data are n (%).
†
Two patients had mCR with hematological improvement without meeting the criteria for CR.